The Chinese biotech, BeiGene, announced the completion of Phase 1 of a more than 1,000,000 square foot biomanufacturing facility in Guangzhou, China.
The facility will focus on commercial-scale manufacturing tislelizumab, the company’s anti-PD-1 antibody, for global use. Tislelizumab will be exported to emerging markets as the first innovative anti-cancer drug developed and manufactured in China.
The project's total expected investment will be more than $300 million USD. The base has established a collaboration with Boehringer Ingelheim, adopting the drugmaker's process control system.
Last month, J Capital Research published a report alleging, among other things, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China." The biotech called the allegations "wild speculations."
